세계 바이오마커 시장 : 규모, 점유율, 동향 분석 보고서 - 유형별, 제품별, 용도별, 질환별, 지역별, 부문별 예측(2024-2030년)

Biomarkers Market Growth & Trends:

The global biomarkers market size is expected to reach USD 194.21 billion by 2030, registering a CAGR of 13.36% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising R&D investments by pharmaceutical and biotechnology companies, increasing number of Contract Research Organizations(CROs), and declining cost of clinical trials in emerging economies are the major driving factors for the industry. In addition, key players leverage various strategies to increase their production capabilities and promote the outreach of their product offerings. In June 2022, Paige announced its collaboration with Janssen to evaluate the potential of an (H&E)-based, (AI)-powered biomarker test, developed by Janssen, to screen for actionable FGFR3 and FGFR2 genomic alterations in patients with bladder cancer.

The increasing prevalence of chronic diseases like cancer, diabetes, and cardiovascular disorders is anticipated to fuel industry growth. According to the American Cancer Society, in 2022, an estimated 1.9 million new cancer cases were registered in the U.S., accounting for 609,360 deaths. Breast and lung cancers were observed as the most common ones worldwide. In addition, according to a report published in 2020 by the Institute for Health Metrics and Evaluation, cardiovascular diseases cause about 18.9 million deaths annually. Increasing research focused on the identification of new diagnostic biomarkers is fueling the industry's growth. For instance, in February 2022, Japanese scientists found two new diagnostic tissue biomarkers, PHGDH and TRIM29, indicated for malignant pleural mesothelioma.

These agents can be used to diagnose mesothelioma quickly and help doctors in differentiating between mesothelioma and other cancers. Moreover, in January 2020, a nascent research study published in the Journal of Nuclear Medicine discussed the potential of several breast cancer biomarkers. A notable and easily identifiable imaging biomarker recognized in the study was 18F-FDG PET. Moreover, the COVID-19 pandemic has encouraged the use of biomarkers for facilitating the detection & treatment of the disease. For instance, in March 2021, a new biomarker-based screening device, named Tiger Tech COVID Plus Monitor, was approved by the U.S. FDA.

The device can be used for the identification of biomarkers for COVID-19 and other hypercoagulable & hyperinflammatory conditions in individuals aged 5 years & above. Furthermore, various strategic initiatives undertaken by leading participants are anticipated to cater to demand. For instance, in August 2022, Roche received the U.S. FDA approval for VENTANA MMR RxDx Panel to detect pMMR endometrial cancer patients and dMMR solid tumor patients eligible for treatment with Merck's immunotherapy Keytruda. This approval for the VENTANA MMR RxDx Panel is a label expansion of the company's recent on-market panel. Also, in December 2021, Siemens Healthineers partnered with Freenome to identify novel suitable markers for the detection of early breast cancer to expand its existing imaging technologies.

Biomarkers Market Report Highlights:

• The safety segment held the largest revenue share of 37.62% in 2023 owing to the increased adoption of safety biomarkers in drug discovery and development
• The efficacy biomarkers segment is expected to grow at the fastest CAGR from 2024 to 2030 due to a rise in strategic collaborations for promoting research activities
• The drug discovery & development segment dominated the market in 2023 due to the extensive R&D efforts taken by leading participants, and the rising adoption of biomarkers in drug discovery
• The cancer segment led the market in 2023 and is expected to retain its dominance from 2024 to 2030. . However, the neurological diseases segment is anticipated to record the fastest CAGR over the forecast years
• Asia Pacific is anticipated to attain the fastest CAGR from 2024 to 2030 due to the rising investments by key players and increasing disease prevalence in the region

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Product
  • 1.2.3. Application
  • 1.2.4. Disease
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for Primary Interviews in North America
    • 1.4.5.2. Data for Primary Interviews in Europe
    • 1.4.5.3. Data for Primary Interviews in Asia Pacific
    • 1.4.5.4. Data for Primary Interviews in Latin America
    • 1.4.5.5. Data for Primary Interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type and product outlook
  • 2.2.2. Application and disease outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Biomarkers Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing funding for biomarkers
    • 3.2.1.2. Increasing prevalence for chronic diseases
    • 3.2.1.3. Technological advancement
    • 3.2.1.4. Growing importance of companion diagnostics
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Lack of reimbursement policies for biomarkers
    • 3.2.2.2. High capital investment and lengthy timelines for biomarker development
  • 3.2.3. Market opportunity analysis
    • 3.2.3.1. Emergence of personalized medicine
    • 3.2.3.2. Emerging economies
  • 3.2.4. Market challenge analysis
    • 3.2.4.1. Challenges associated with biomarkers validation
    • 3.2.4.2. Technical issues related to sample collection and storage
• 3.3. Biomarkers Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pricing Analysis
    • 3.3.3.1. Selling price of biomarker by top players

Chapter 4. Biomarkers Market: Type Estimates & Trend Analysis

• 4.1. Type Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Biomarkers Market by Type Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Safety biomarkers
    • 4.4.1.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.2. Efficacy biomarkers
    • 4.4.2.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.3. Predictive biomarkers
    • 4.4.3.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.4. Surrogate biomarkers
    • 4.4.4.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.5. Pharmacodynamic biomarkers
    • 4.4.5.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.6. Prognostics biomarkers
    • 4.4.6.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.7. Validation biomarkers
    • 4.4.7.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Biomarkers Market: Product Estimates & Trend Analysis

• 5.1. Product Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Biomarkers Market by Product Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Consumables
    • 5.4.1.1. Consumables market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.2. Services
    • 5.4.2.1. Services market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.3. Software
    • 5.4.3.1. Software market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Biomarkers Market: Application Estimates & Trend Analysis

• 6.1. Application Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Biomarkers Market by Application Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Diagnostics
    • 6.4.1.1. Diagnostics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4.2. Drug Discovery and Development
    • 6.4.2.1. Drug discovery and development market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4.3. Personalized Medicine
    • 6.4.3.1. Personalized medicine market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4.4. Disease Risk Assessment
    • 6.4.4.1. Disease risk assessment market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4.5. Others
    • 6.4.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Biomarkers Market: Disease Estimates & Trend Analysis

• 7.1. Disease Market Share, 2023 & 2030
• 7.2. Segment Dashboard
• 7.3. Global Biomarkers Market by Disease Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.4.1. Cancer
    • 7.4.1.1. Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.1.2. Safety biomarkers
    • 7.4.1.2.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.1.3. Efficacy biomarkers
    • 7.4.1.3.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.1.4. Predictive biomarkers
    • 7.4.1.4.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.1.5. Surrogate biomarkers
    • 7.4.1.5.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.1.6. Pharmacodynamic biomarkers
    • 7.4.1.6.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.1.7. Prognostics biomarkers
    • 7.4.1.7.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.1.8. Validation biomarkers
    • 7.4.1.8.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.2. Cardiovascular Diseases
    • 7.4.2.1. Cardiovascular diseases market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.2.2. Safety biomarkers
    • 7.4.2.2.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.2.3. Efficacy biomarkers
    • 7.4.2.3.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.2.4. Predictive biomarkers
    • 7.4.2.4.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.2.5. Surrogate biomarkers
    • 7.4.2.5.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.2.6. Pharmacodynamic biomarkers
    • 7.4.2.6.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.2.7. Prognostics biomarkers
    • 7.4.2.7.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.2.8. Validation biomarkers
    • 7.4.2.8.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)Neurological Diseases
    • 7.4.3.1. Neurological diseases market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.3.2. Safety biomarkers
    • 7.4.3.2.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.3.3. Efficacy biomarkers
    • 7.4.3.3.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.3.4. Predictive biomarkers
    • 7.4.3.4.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.3.5. Surrogate biomarkers
    • 7.4.3.5.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.3.6. Pharmacodynamic biomarkers
    • 7.4.3.6.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.3.7. Prognostics biomarkers
    • 7.4.3.7.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.3.8. Validation biomarkers
    • 7.4.3.8.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.4. Immunological Diseases
    • 7.4.4.1. Immunological diseases market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.4.2. Safety biomarkers
    • 7.4.4.2.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.4.3. Efficacy biomarkers
    • 7.4.4.3.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.4.4. Predictive biomarkers
    • 7.4.4.4.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.4.5. Surrogate biomarkers
    • 7.4.4.5.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.4.6. Pharmacodynamic biomarkers
    • 7.4.4.6.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.4.7. Prognostics biomarkers
    • 7.4.4.7.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.4.8. Validation biomarkers
    • 7.4.4.8.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.5. Others
    • 7.4.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.5.2. Safety biomarkers
    • 7.4.5.2.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.5.3. Efficacy biomarkers
    • 7.4.5.3.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.5.4. Predictive biomarkers
    • 7.4.5.4.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.5.5. Surrogate biomarkers
    • 7.4.5.5.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.5.6. Pharmacodynamic biomarkers
    • 7.4.5.6.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.5.7. Prognostics biomarkers
    • 7.4.5.7.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.5.8. Validation biomarkers
    • 7.4.5.8.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Biomarkers Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2023 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.5. North America
  • 8.5.1. U.S.
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.2. Canada
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.6. Europe
  • 8.6.1. UK
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6.2. Germany
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6.3. France
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ reimbursement structure
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6.4. Italy
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework/ reimbursement structure
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6.5. Spain
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework/ reimbursement structure
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6.6. Norway
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework/ reimbursement structure
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6.7. Sweden
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework/ reimbursement structure
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6.8. Denmark
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory framework/ reimbursement structure
    • 8.6.8.3. Competitive scenario
    • 8.6.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Japan
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.2. China
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.3. India
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.4. Australia
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.5. South Korea
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework/ reimbursement structure
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.6. Thailand
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework/ reimbursement structure
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.8. Latin America
  • 8.8.1. Brazil
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Regulatory framework/ reimbursement structure
    • 8.8.1.3. Competitive scenario
    • 8.8.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.8.2. Mexico
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework/ reimbursement structure
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.8.3. Argentina
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Regulatory framework/ reimbursement structure
    • 8.8.3.3. Competitive scenario
    • 8.8.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.9. MEA
  • 8.9.1. South Africa
    • 8.9.1.1. Key country dynamics
    • 8.9.1.2. Regulatory framework/ reimbursement structure
    • 8.9.1.3. Competitive scenario
    • 8.9.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.9.2. Saudi Arabia
    • 8.9.2.1. Key Country Dynamics
    • 8.9.2.2. Regulatory framework/ reimbursement structure
    • 8.9.2.3. Competitive scenario
    • 8.9.2.4. Saudi Arabia market estimates and forecasts for 2018 to 2030 (USD Million)
  • 8.9.3. UAE
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory framework/ reimbursement structure
    • 8.9.3.3. Competitive scenario
    • 8.9.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.9.4. Kuwait
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory framework/ reimbursement structure
    • 8.9.4.3. Competitive scenario
    • 8.9.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. List of key distributors and channel partners
  • 9.3.2. Key customers
  • 9.3.3. Key company market share analysis, 2023
  • 9.3.4. F. Hoffmann-La Roche Ltd.
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Abbott
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Epigenomics AG
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. General Electric
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Johnson & Johnson Services, Inc.
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Thermo Fisher Scientific Inc.
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Bio-Rad Laboratories, Inc.
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Siemens Healthineers AG
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. QIAGEN
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Product benchmarking
    • 9.3.12.4. Strategic initiatives
  • 9.3.13. Merck KGaA
    • 9.3.13.1. Company overview
    • 9.3.13.2. Financial performance
    • 9.3.13.3. Product benchmarking
    • 9.3.13.4. Strategic initiatives
  • 9.3.14. PerkinElmer Inc.
    • 9.3.14.1. Company overview
    • 9.3.14.2. Financial performance
    • 9.3.14.3. Product benchmarking
    • 9.3.14.4. Strategic initiatives
  • 9.3.15. Agilent Technologies, Inc.
    • 9.3.15.1. Company overview
    • 9.3.15.2. Financial performance
    • 9.3.15.3. Product benchmarking
    • 9.3.15.4. Strategic initiatives
  • 9.3.16. Eurofins Scientific
    • 9.3.16.1. Company overview
    • 9.3.16.2. Financial performance
    • 9.3.16.3. Product benchmarking
    • 9.3.16.4. Strategic initiatives